Rio Handa
YOU?
Author Swipe
View article: Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-<i>meta</i>-iodobenzylguanidine
Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-<i>meta</i>-iodobenzylguanidine Open
The rare abscopal effect in radiotherapy is thought to result from immune-activating damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), released from cancer cells. While external irradiation of cancer …
View article: Release of HMGB1 from Human-Derived Cancer and Normal Cells by Internal Targeted Radiotherapy with <sup>131</sup>Iodine-Labeled <em>m</em>-Iodobenzylguanidine
Release of HMGB1 from Human-Derived Cancer and Normal Cells by Internal Targeted Radiotherapy with <sup>131</sup>Iodine-Labeled <em>m</em>-Iodobenzylguanidine Open
The rare abscopal effect during radiotherapy is thought to be caused by the release of immune-stimulated damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), from cancer cells. Although external irradiat…
View article: The Efficiency of 18F-FDG-PET/CT in Assessment of Tumor Response to Preoperative Chemoradiation Therapy for Locally Recurrent Rectal Cancer
The Efficiency of 18F-FDG-PET/CT in Assessment of Tumor Response to Preoperative Chemoradiation Therapy for Locally Recurrent Rectal Cancer Open
Background: Locally recurrent rectal cancer (LRRC) remains a major problem after curative resection of primary rectal cancer. A noninvasive biomarker that accurately evaluates the disease status and assesses the treatment response with pro…
View article: Additional file 1 of The efficiency of 18F-FDG-PET/CT in the assessment of tumor response to preoperative chemoradiation therapy for locally recurrent rectal cancer
Additional file 1 of The efficiency of 18F-FDG-PET/CT in the assessment of tumor response to preoperative chemoradiation therapy for locally recurrent rectal cancer Open
Additional file 1: Supplementary Fig. 1. Uptake of 18F-fluorodeoxyglucose measured in patients included in the pilot phase of the study (n = 12), in which Pre-SUV, Mid-SUV (2 weeks after initiation of CRT), and Post-SUV (3 weeks after comp…